Universal Beteiligungs und Servicegesellschaft mbH Sells 5,137 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Universal Beteiligungs und Servicegesellschaft mbH cut its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 4.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 119,545 shares of the medical equipment provider’s stock after selling 5,137 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.06% of Zimmer Biomet worth $10,904,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Ameriprise Financial Inc. boosted its holdings in Zimmer Biomet by 236.0% in the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock valued at $517,039,000 after purchasing an additional 3,208,596 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Zimmer Biomet by 251.3% in the first quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock valued at $235,571,000 after buying an additional 1,488,918 shares during the period. Nuveen LLC bought a new stake in shares of Zimmer Biomet in the first quarter valued at about $155,891,000. Alyeska Investment Group L.P. acquired a new stake in Zimmer Biomet during the first quarter worth about $101,294,000. Finally, Dodge & Cox increased its stake in Zimmer Biomet by 2.3% during the first quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider’s stock valued at $2,214,305,000 after acquiring an additional 446,018 shares during the period. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Up 0.5%

Shares of NYSE ZBH opened at $89.50 on Thursday. Zimmer Biomet Holdings, Inc. has a 52-week low of $85.33 and a 52-week high of $114.44. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.96 and a current ratio of 1.87. The business has a fifty day moving average of $97.69 and a two-hundred day moving average of $96.79. The stock has a market cap of $17.74 billion, a PE ratio of 21.78, a PEG ratio of 2.29 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The business had revenue of $2 billion during the quarter, compared to analysts’ expectations of $2.01 billion. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. During the same quarter last year, the company posted $1.74 EPS. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend was Tuesday, September 30th. Zimmer Biomet’s payout ratio is presently 23.76%.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Roth Capital reissued a “buy” rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Royal Bank Of Canada reduced their target price on Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday, November 6th. BTIG Research lowered their price target on shares of Zimmer Biomet from $122.00 to $112.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a research note on Wednesday, October 8th. Finally, Stifel Nicolaus set a $110.00 target price on shares of Zimmer Biomet in a research report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $109.00.

Insider Buying and Selling

In related news, SVP Lori Winkler sold 1,500 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the sale, the senior vice president directly owned 6,833 shares in the company, valued at $711,656.95. This represents a 18.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.39% of the stock is currently owned by company insiders.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.